Skip to content
10-Q

Quarterly Report

Citius Pharmaceuticals, Inc. CTXR

0001213900-26-057842

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · May 14, 2026 27.45M sh
Shares Diluted Q2 2026 · Mar 31, 2026 22.38M sh
Shares Diluted Q2 2026 · Mar 31, 2026 21.93M sh
Shares Diluted Q2 2026 · Mar 31, 2025 8.58M sh
Shares Diluted Q2 2026 · Mar 31, 2025 8.03M sh
Operating Cash Flow Q2 2026 · Mar 31, 2026 −$14.31M
Operating Cash Flow Q2 2026 · Mar 31, 2025 −$9.27M
Cash And Equivalents Q2 2026 · Mar 31, 2026 $4.59M
Cash And Equivalents Q2 2026 · Sep 30, 2025 $4.25M
Stockholders Equity Q2 2026 · Mar 31, 2026 $61.54M
Stockholders Equity Q2 2026 · Sep 30, 2025 $67.55M
Current Liabilities Q2 2026 · Mar 31, 2026 $55.02M
Current Liabilities Q2 2026 · Sep 30, 2025 $44.91M
Total Liabilities Q2 2026 · Mar 31, 2026 $63.46M
Total Liabilities Q2 2026 · Sep 30, 2025 $53.41M
Current Assets Q2 2026 · Mar 31, 2026 $31.69M
Current Assets Q2 2026 · Sep 30, 2025 $27.93M
Total Assets Q2 2026 · Mar 31, 2026 $132.54M
Total Assets Q2 2026 · Sep 30, 2025 $130.94M
Eps Diluted Q2 2026 · Mar 31, 2026 −$0.95
Eps Diluted Q2 2026 · Mar 31, 2026 −$1.34
Eps Diluted Q2 2026 · Mar 31, 2025 −$1.27
Eps Diluted Q2 2026 · Mar 31, 2025 −$2.58
Eps Basic Q2 2026 · Mar 31, 2026 −$0.95
Eps Basic Q2 2026 · Mar 31, 2026 −$1.34
Eps Basic Q2 2026 · Mar 31, 2025 −$1.27
Eps Basic Q2 2026 · Mar 31, 2025 −$2.58
Sga Expense Q2 2026 · Mar 31, 2026 $26.39M
Sga Expense Q2 2026 · Mar 31, 2026 $32.11M
Sga Expense Q2 2026 · Mar 31, 2025 $4.79M
Sga Expense Q2 2026 · Mar 31, 2025 $10.18M
Rd Expense Q2 2026 · Mar 31, 2026 $1.63M
Rd Expense Q2 2026 · Mar 31, 2026 $3.23M
Rd Expense Q2 2026 · Mar 31, 2025 $3.77M
Rd Expense Q2 2026 · Mar 31, 2025 $5.89M
Operating Income Q2 2026 · Mar 31, 2026 −$32.19M
Operating Income Q2 2026 · Mar 31, 2026 −$41.21M
Operating Income Q2 2026 · Mar 31, 2025 −$11.26M
Operating Income Q2 2026 · Mar 31, 2025 −$21.3M
Gross Profit Q2 2026 · Mar 31, 2026 $1.34M
Gross Profit Q2 2026 · Mar 31, 2026 $4.49M
Cost Of Revenue Q2 2026 · Mar 31, 2026 $328.88K
Cost Of Revenue Q2 2026 · Mar 31, 2026 $1.12M
Revenue Q2 2026 · Mar 31, 2026 $1.67M
Revenue Q2 2026 · Mar 31, 2026 $5.61M